摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1,1-dimethylethyl 4-(4-fluoro-6-methyl-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)-1-piperidinecarboxylate | 932373-58-5

中文名称
——
中文别名
——
英文名称
1,1-dimethylethyl 4-(4-fluoro-6-methyl-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)-1-piperidinecarboxylate
英文别名
tert-butyl 4-(4-fluoro-6-methyl-2-oxo-3H-benzimidazol-1-yl)piperidine-1-carboxylate
1,1-dimethylethyl 4-(4-fluoro-6-methyl-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)-1-piperidinecarboxylate化学式
CAS
932373-58-5
化学式
C18H24FN3O3
mdl
——
分子量
349.405
InChiKey
ZVHOWAPFATVRBO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.7
  • 重原子数:
    25
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.56
  • 拓扑面积:
    61.9
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

反应信息

点击查看最新优质反应信息

文献信息

  • Compounds which have activity at M1 receptor and their uses in medicine.
    申请人:Budzik Brian
    公开号:US20080058378A1
    公开(公告)日:2008-03-06
    Compounds of formula (I) and salts and solvates are provided: wherein R 4 is fluoro, R 5 is selected from hydrogen, halogen, cyano, C 1-6 alkyl, C 1-6 alkyl substituted with one or more fluorine atoms, C 1-6 alkoxy, and C 1-6 alkoxy substituted with one or more fluorine atoms; and R 6 is selected from halogen, cyano, C 1-6 alkyl, C 1-6 alkyl substituted with one or more fluorine atoms, C 3-6 cycloalkyl, C 3-6 cycloalkyl substituted with one or more fluorine atoms, C 1-6 alkoxy and C 1-6 alkoxy substituted with one or more fluorine atoms, and Q is hydrogen or C 1-6 alkyl. The compounds are expected to be useful for therapy, for example in the treatment of psychotic disorders and cognitive impairment.
    提供了式(I)的化合物及其盐和溶剂化物: 其中R4为氟,R5选自氢、卤素、氰基、C1-6烷基、一种或多种氟原子取代的C1-6烷基、C1-6烷氧基和一种或多种氟原子取代的C1-6烷氧基;R6选自卤素、氰基、C1-6烷基、一种或多种氟原子取代的C1-6烷基、C3-6环烷基、一种或多种氟原子取代的C3-6环烷基、C1-6烷氧基和一种或多种氟原子取代的C1-6烷氧基,Q为氢或C1-6烷基。这些化合物预计在治疗方面有用,例如在治疗精神障碍和认知障碍方面。
  • Compounds Which Have Activity at M1 Receptor and Their Uses in Medicine
    申请人:Budzik Brian
    公开号:US20080255195A1
    公开(公告)日:2008-10-16
    Compounds of formula (I) and salts are provided: wherein R 4 is fluoro, R 5 is selected from hydrogen, halogen, cyano, C 1-6 alkyl, C 1-6 alkyl substituted with one or more fluorine atoms, C 1-6 alkoxy, and C 1-6 alkoxy substituted with one or more fluorine atoms; and R 6 is selected from halogen, cyano, C 1-6 alkyl, C 1-6 alkyl substituted with one or more fluorine atoms, C 3-6 cycloalkyl, C 3-6 cycloalkyl substituted with one or more fluorine atoms, C 1-6 alkoxy and C 1-6 alkoxy substituted with one or more fluorine atoms, and Q is hydrogen or C 1-6 alkyl. The compounds are expected to be useful for therapy, for example in the treatment of psychotic disorders and cognitive impairment.
    提供了化学式(I)和盐的化合物:其中R4为氟,R5从氢,卤素,氰基,C1-6烷基,C1-6烷基取代物,其中取代了一个或多个氟原子,C1-6烷氧基和C1-6烷氧基取代物中选择; R6从卤素,氰基,C1-6烷基,C1-6烷基取代物中选择,其中取代了一个或多个氟原子,C3-6环烷基,C3-6环烷基取代物中选择一个或多个氟原子,C1-6烷氧基和C1-6烷氧基取代物,Q为氢或C1-6烷基。预计这些化合物在治疗中会有用,例如在治疗精神障碍和认知障碍方面。
  • Compounds which have activity at M1 receptor and their uses in medicine
    申请人:Glaxo Group Limited
    公开号:US08283364B2
    公开(公告)日:2012-10-09
    Compounds of formula (I) and salts are provided: wherein R4 is fluoro, R5 is selected from hydrogen, halogen, cyano, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C1-6alkoxy, and C1-6alkoxy substituted with one or more fluorine atoms; and R6 is selected from halogen, cyano, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C3-6cycloalkyl, C3-6cycloalkyl substituted with one or more fluorine atoms, C1-6alkoxy and C1-6alkoxy substituted with one or more fluorine atoms, and Q is hydrogen or C1-6alkyl. The compounds are expected to be useful for therapy, for example in the treatment of psychotic disorders and cognitive impairment.
    提供了公式(I)和盐的化合物:其中R4为氟,R5选择自氢,卤素,氰基,C1-6烷基,C1-6烷基取代一个或多个氟原子,C1-6烷氧基和C1-6烷氧基取代一个或多个氟原子; R6选择自卤素,氰基,C1-6烷基,C1-6烷基取代一个或多个氟原子,C3-6环烷基,C3-6环烷基取代一个或多个氟原子,C1-6烷氧基和C1-6烷氧基取代一个或多个氟原子,Q为氢或C1-6烷基。这些化合物预计在治疗中有用,例如用于治疗精神障碍和认知障碍。
  • WO2007/36715
    申请人:——
    公开号:——
    公开(公告)日:——
  • WO2007036715A2
    申请人:——
    公开号:——
    公开(公告)日:——
查看更多